Similar articles

• What CATIE found: results from the schizophrenia trial.

  Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA. Swartz MS, et al. Psychiatr Serv. 2008 May;59(5):500-6. doi: 10.1176/ps.2008.59.5.500. Psychiatr Serv. 2008. PMID: 18451005 Free PMC article. Clinical Trial.
• Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.

  Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P. Kongsakon R, et al. J Med Assoc Thai. 2005 Sep;88(9):1267-77. J Med Assoc Thai. 2005. PMID: 16536115
• Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.

  Park T, Kuntz KM. Park T, et al. Value Health. 2014 Jun;17(4):310-9. doi: 10.1016/j.jval.2014.02.008. Epub 2014 May 10. Value Health. 2014. PMID: 24968989
• An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.

  Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, Holland R. Montgomery JH, et al. Control Clin Trials. 2004 Dec;25(6):598-612. doi: 10.1016/j.cct.2004.09.002. Control Clin Trials. 2004. PMID: 15588746 Review.
• Pharmacology of antipsychotics in the elderly: a focus on atypicals.

  Finkel S. Finkel S. J Am Geriatr Soc. 2004 Dec;52(12 Suppl):S258-65. doi: 10.1111/j.1532-5415.2004.52602.x. J Am Geriatr Soc. 2004. PMID: 15541166 Review. No abstract available.